Skip to main content

enGene Therapeutics Inc.

ENGN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001980845

In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.

Other share classesENGNW

13F holders, Q2 2024

Institutional positions in enGene Therapeutics Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
30
−1 vs. Q1 2024
Shares held
32.6M
+951.1K (+3.0%) vs. Q1 2024
Total value
$307.1M
−$228.9M (−42.7%) vs. Q1 2024
New holders
6
8 more added
Sold out
7
6 more reduced

Compare with Q1 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ENGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2024: 30 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 0 institutionsQ1 2023: 0 institutionsQ2 2023: 0 institutionsQ3 2023: 0 institutionsQ4 2023: 11 institutionsQ1 2024: 31 institutionsQ2 2024: 30 institutionsQ3 2024: 30 institutionsQ4 2024: 34 institutionsQ1 2025: 31 institutionsQ2 2025: 36 institutionsQ3 2025: 37 institutionsQ4 2025: 58 institutionsQ1 2026: 62 institutionsQ2 2026: 60 institutions
Value heldQ2 2024: $307.1M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $0Q4 2023: $130.9MQ1 2024: $536.1MQ2 2024: $307.1MQ3 2024: $227.7MQ4 2024: $274.7MQ1 2025: $183.4MQ2 2025: $147.1MQ3 2025: $279.1MQ4 2025: $530.8MQ1 2026: $383.0MQ2 2026: $86.5M
Institutions holding ENGN and their total value by quarter
QuarterHoldersValue
Q2 202660$86.5M
Q1 202662$383.0M
Q4 202558$530.8M
Q3 202537$279.1M
Q2 202536$147.1M
Q1 202531$183.4M
Q4 202434$274.7M
Q3 202430$227.7M
Q2 202430$307.1M
Q1 202431$536.1M
Q4 202311$130.9M
Q3 20230$0
Q2 20230$0
Q1 20230$0
Q4 20220$0
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q2 2024

Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q1 2024.

Institutions holding ENGN in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
FCPM III Services B.V.8,677,951$81.8M12.07%00.0%Unchanged
Adage Capital Partners GP, L.L.C.3,300,000$31.1M0.06%+2,100,000+175.0%Added
VR Adviser, LLC2,825,983$26.6M1.70%+260,142+10.1%Added
Blue Owl Capital Holdings LP2,449,827$23.1M6.43%−11,523−0.5%Reduced
BVF Inc2,251,037$21.2M0.59%00.0%Unchanged
Deep Track Capital, LP2,250,000$21.2M0.63%00.0%Unchanged
Logos Global Management LP1,200,000$11.3M1.30%+400,000+50.0%Added
Omega Fund Management, LLC1,076,357$10.2M7.52%00.0%Unchanged
Cormorant Asset Management, LP1,000,000$9.43M0.55%00.0%Unchanged
Janus Henderson Group PLC1,000,000$9.04M0.00%00.0%Unchanged
Franklin Resources Inc800,034$7.54M0.00%+340.0%Added
Perceptive Advisors LLC800,000$7.54M0.18%−198,888−19.9%Reduced
Soleus Capital Management, L.P.800,000$7.54M0.67%00.0%Unchanged
Marshall Wace, LLP764,645$7.21M0.01%−35,355−4.4%Reduced
Boxer Capital, LLC727,900$6.86M0.36%00.0%Unchanged
Vivo Capital, LLC678,705$6.40M0.59%00.0%Unchanged
Citadel Advisors LLC613,292$5.78M0.01%−190,886−23.7%Reduced
Sr One Capital Management, LP500,000$4.71M1.48%+500,000New
Ghost Tree Capital, LLC420,331$3.96M1.38%+220,331+110.2%Added
Silverarc Capital Management, LLC263,841$2.49M0.61%+263,841New
Schonfeld Strategic Advisors LLC97,000$914.7K0.01%+46,300+91.3%Added
Point72 Asset Management, L.P.43,900$414.0K0.00%−138,686−76.0%Reduced
Geode Capital Management, LLC27,516$259.5K0.00%+11,390+70.6%Added
Verition Fund Management LLC14,843$140.0K0.00%−47,579−76.2%Reduced
Ameriprise Financial Inc12,524$118.1K0.00%+12,524New
Royal Bank of Canada7,915$75.0K0.00%00.0%Unchanged
UBS Group AG3,370$31.8K0.00%+3,370New
Wells Fargo & Company972$9.17K0.00%+972New
ADAR1 Capital Management, LLC600$5.66K0.00%+600New
Morgan Stanley58$5470.00%+50+625.0%Added
Commodore Capital LP0$00.00%−1,250,000−100.0%Sold out
Deerfield Management Company, L.P. (Series C)0$00.00%−800,000−100.0%Sold out
Altitude Crest Partners Inc.0$00.00%−120,289−100.0%Sold out
Polar Asset Management Partners Inc.0$00.00%−65,225−100.0%Sold out
Cubist Systematic Strategies, LLC0$00.00%−9,757−100.0%Sold out
JPMorgan Chase & Co0$00.00%−289−100.0%Sold out
Qube Research & Technologies Ltd0$00.00%−14−100.0%Sold out